NEW YORK (GenomeWeb) – TAI Diagnostics, a developer of diagnostic tests for monitoring the health of transplanted organs, said on Monday that it has closed a $10 million Series A preferred equity financing.

TAI will use proceeds from the new financing to support ongoing R&D on its PCR-based cell-free DNA transplant monitoring technology, clinical studies, and the upcoming commercial launch of its post-transplant monitoring assays performed in its CLIA- and CAP-accredited laboratory.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.